Article
Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
International journal of molecular sciences - 23 Dec 2019
Dratkiewicz Ewelina, Simiczyjew Aleksandra, Pietraszek-Gremplewicz Katarzyna, Mazurkiewicz Justyna, Nowak Dorota
Abstract excerpt
Constitutively active mutated BRAF kinase occurs in more than 40% of patients suffering from melanoma. To block its activity, a specific inhibitor, vemurafenib, is applied as a therapy. Unfortunately, patients develop resistance to this drug rather quickly. Previously, we demonstrated that pairs of inhibitors directed against EGFR (epidermal growth factor receptor) and MET (hepatocyte growth factor receptor)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.